title: Review and update of central serous chorioretinopathy.
abstract: OBJECTIVE
  Greater understanding of central serous chorioretinopathy (CSCR) has changed initial beliefs that CSCR is a benign condition affecting young men with almost complete resolution. CSCR has a spectrum of presentations with more diffuse retinal dysfunction and variations between races. CSCR can affect older individuals and in a subset of patients may lead to significant ocular morbidity.
  
  
  RESULTS
  Advances in imaging, particularly in indocyanine green angiography and optical coherence tomography, have led to a greater understanding of the pathophysiology of this condition. Treatments for CSCR are still evolving, in particular photodynamic dynamic therapy using lower doses and reduced fluence showing promising results. More research is required on ideal dosage. Anti-vascular endothelial growth factor treatment offers a new medical treatment modality with promising results.
  
  
  CONCLUSIONS
  There have been recent imaging developments in addition to therapeutic advances for refractory CSCR.
authors.affiliation: Ophthalmology Department, Cheltenham General Hospital, Gloucestershire, UK.
authors.forename: Alexander
authors.initials: A
authors.lastname: Ross
authors.forename: Adam H
authors.initials: AH
authors.lastname: Ross
authors.forename: Quresh
authors.initials: Q
authors.lastname: Mohamed
mesh_terms: D056833:Central Serous Chorioretinopathy / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans